The New England Journal of Medicine MAY 26, 2022

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Non-Small-Cell Lung Cancer (CheckMate 816)

Patrick M. Forde, Jonathan D. Spicer, Mariano Provencio, et al.

Bottom Line

The CheckMate 816 trial demonstrated that the addition of neoadjuvant nivolumab to platinum-doublet chemotherapy significantly improves event-free survival (EFS), pathologic complete response (pCR) rates, and long-term overall survival (OS) in patients with resectable stage IB to IIIA non-small-cell lung cancer.

Key Findings

1. The combination of nivolumab plus chemotherapy demonstrated a significant OS benefit, with a 5-year OS rate of 65% compared to 55% with chemotherapy alone (HR 0.72; P=0.0479).

2. Event-free survival was significantly improved with the addition of nivolumab, showing a median EFS of 31.6 months versus 20.8 months in the chemotherapy-only arm (HR 0.63; P=0.005).

3. Pathologic complete response (pCR) rates were markedly higher in the experimental arm, reaching 24.0% versus 2.2% in the control arm (OR 13.94; P<0.001).

4. The neoadjuvant chemoimmunotherapy regimen did not increase the incidence of grade 3 or 4 treatment-related adverse events or impede the feasibility of subsequent definitive surgical resection compared to chemotherapy alone.

5. Exploratory analyses indicated that both pCR and the clearance of circulating tumor DNA (ctDNA) following neoadjuvant treatment were strong indicators of improved long-term survival.

Study Design

Design

RCT

Open-Label

Sample

358

Patients

Duration

5.7 yr

Median

Setting

Multicenter, Global

Population Adult patients with newly diagnosed resectable stage IB (≥4 cm) to IIIA non-small-cell lung cancer (NSCLC) with an ECOG performance status of 0 or 1, and no known EGFR or ALK genomic alterations.

Intervention Three cycles of neoadjuvant nivolumab (360 mg) plus platinum-doublet chemotherapy every 3 weeks followed by surgery.

Comparator Three cycles of neoadjuvant platinum-doublet chemotherapy alone every 3 weeks followed by surgery.

Outcome Pathologic complete response (pCR) and event-free survival (EFS) assessed by blinded independent central review.

Study Limitations

• The trial specifically excluded patients with actionable genomic alterations (e.g., EGFR mutations or ALK fusions), limiting the generalizability of the findings to these specific subgroups.

• While the OS benefit was statistically significant, the study was open-label, which can introduce performance bias, although primary endpoints were assessed by blinded independent review.

• Variability in the type of adjuvant therapy permitted after surgery may have introduced heterogeneity in the post-operative management of patients across both arms.

• The trial was not powered to determine the incremental benefit of adjuvant therapy following the successful completion of the neoadjuvant regimen.

Clinical Significance

CheckMate 816 establishes neoadjuvant chemoimmunotherapy with nivolumab as a new standard-of-care for resectable NSCLC. By achieving high pCR rates and improving long-term overall survival without significant toxicity, this approach enables a curative-intent strategy for locally advanced disease, effectively shifting the paradigm of perioperative management.

Historical Context

Historically, the benefit of chemotherapy in the neoadjuvant or adjuvant setting for resectable NSCLC has been modest. CheckMate 816 represents a milestone as the first phase III trial of neoadjuvant-only chemoimmunotherapy to demonstrate a statistically significant overall survival benefit, providing clinical validation for the use of immune checkpoint inhibitors in earlier, potentially curative stages of lung cancer.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

What is the biological rationale for using an immune checkpoint inhibitor like nivolumab in the neoadjuvant (pre-surgical) setting rather than the adjuvant (post-surgical) setting for NSCLC?

Key Response

In the neoadjuvant setting, the primary tumor and regional lymph nodes are still present, providing a higher level of tumor-derived antigens. This allows for a more robust priming and expansion of tumor-specific T cells, which can then circulate as memory cells to eliminate micrometastatic disease after the primary tumor is surgically removed.

Resident

In CheckMate 816, did the addition of nivolumab to chemotherapy increase the rate of surgical cancellations or delays compared to chemotherapy alone?

Key Response

The study found that the addition of nivolumab did not increase the rate of surgical complications or delays. In fact, more patients in the nivolumab-plus-chemotherapy group underwent definitive surgery (83% vs. 75%) and had a higher rate of minimally invasive surgery, suggesting that neoadjuvant chemo-immunotherapy may improve surgical feasibility by reducing tumor burden.

Fellow

How should the results of CheckMate 816 influence the management of patients with known EGFR or ALK alterations who present with resectable stage IIIA NSCLC?

Key Response

CheckMate 816 excluded patients with known sensitizing EGFR mutations or ALK translocations. These subgroups generally respond poorly to immunotherapy and have distinct treatment pathways (e.g., adjuvant osimertinib from the ADAURA trial). Therefore, molecular testing should be performed prior to initiating neoadjuvant chemo-immunotherapy to ensure appropriate targeted therapy is not delayed or replaced by a less effective regimen.

Attending

Given the significant improvement in pCR and EFS in CheckMate 816, if a patient achieves a pathological complete response (pCR) after neoadjuvant chemo-IO, is there a clinical role for additional adjuvant immunotherapy?

Key Response

This is a key area of current debate. CheckMate 816 did not mandate adjuvant immunotherapy. While trials like KEYNOTE-671 and CheckMate 77T (perioperative trials) include adjuvant IO, we do not yet have head-to-head data to prove if adjuvant IO provides additional benefit to those who already achieved a pCR from neoadjuvant therapy. Practice is currently shifting toward the 'perioperative' approach (neoadjuvant + adjuvant), but de-escalation for pCR patients is a major research focus.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

To what extent can Pathologic Complete Response (pCR) be considered a validated surrogate endpoint for Overall Survival (OS) in immunotherapy-based neoadjuvant trials compared to traditional cytotoxic trials?

Key Response

In traditional chemotherapy trials, pCR has had a variable correlation with OS in NSCLC. However, CheckMate 816 data showed a strong association between achieving pCR and improved EFS. From a methodology standpoint, validating pCR as a surrogate requires large-scale meta-analyses and long-term OS data to ensure that the immune-mediated changes in the tumor microenvironment translate to durable systemic control differently than chemotherapy-induced cell death.

Journal Editor

One notable observation in CheckMate 816 was the higher benefit observed in patients with PD-L1 expression ≥1% and those with squamous histology. Does the trial design sufficiently address whether PD-L1 <1% patients derive enough benefit to justify the costs and potential risks of adding nivolumab?

Key Response

While the trial showed benefit across most subgroups, the hazard ratio for EFS was less impressive in the PD-L1 <1% group (0.85) compared to the ≥1% group (0.41). A critical reviewer would flag that the study may be underpowered for this subgroup and question whether a biomarker-agnostic approval is appropriate or if a more nuanced recommendation should be made for PD-L1 negative patients.

Guideline Committee

Based on CheckMate 816, should NCCN or ASCO guidelines recommend neoadjuvant nivolumab-chemotherapy as a Category 1 recommendation for all patients with stage IB-IIIA NSCLC, and what prerequisites for molecular screening should be mandated?

Key Response

CheckMate 816 has led to Category 1 recommendations in NCCN guidelines for resectable NSCLC (≥4cm or node-positive). However, the committee must emphasize the necessity of EGFR/ALK testing before treatment. Current guidelines now specify that neoadjuvant chemo-IO is preferred, but they must balance this against the results of adjuvant-only trials (IMpower010) and ensure the staging is performed via EBUS/mediastinoscopy to accurately define the IIIA population benefiting from this approach.

Clinical Landscape

Noteworthy Related Trials

2017

PACIFIC Trial

n = 713 · NEJM

Tested

Durvalumab

Population

Stage III unresectable NSCLC

Comparator

Placebo

Endpoint

Progression-free survival and overall survival

Key result: Durvalumab consolidation therapy significantly prolonged progression-free and overall survival compared to placebo.

2021

IMpower010 Trial

n = 1280 · Lancet

Tested

Atezolizumab

Population

Resected Stage IB-IIIA NSCLC

Comparator

Best supportive care

Endpoint

Disease-free survival

Key result: Atezolizumab following adjuvant chemotherapy significantly improved disease-free survival in patients with PD-L1 positive tumors.

2022

KEYNOTE-091/PEARLS Trial

n = 1177 · Lancet Oncol

Tested

Pembrolizumab

Population

Resected Stage IB-IIIA NSCLC

Comparator

Placebo

Endpoint

Disease-free survival

Key result: Adjuvant pembrolizumab resulted in significantly longer disease-free survival compared with placebo in the overall population.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis